Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer Survival Analysis01:21

Cancer Survival Analysis

346
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
346
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. A Robust Primary Liver Cancer Subtype Related To Prognosis And Drug Response Based On A Multiple Combined Classifying Strategy.
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. A Robust Primary Liver Cancer Subtype Related To Prognosis And Drug Response Based On A Multiple Combined Classifying Strategy.

Related Experiment Video

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.2K

A robust primary liver cancer subtype related to prognosis and drug response based on a multiple combined classifying strategy.

Jielian Deng1,2, Guichuan Lai1, Cong Zhang1

  • 1Department of Epidemiology and Health Statistics, School of Public Health, Chongqing Medical University, Chongqing, China.

Heliyon
|February 14, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

This study classifies primary liver cancer (PLC) patients into subtypes using integrated risk scores and immune data. The mRNAsiH_ICCA subtype shows the worst prognosis, guiding precision medicine for liver cancer treatment.

Keywords:
Cancer molecular markersCancer stem cellsCombined classifyingDrug sensitivity

More Related Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.2K
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.3K

Related Experiment Videos

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.2K
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.2K
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.3K

Area of Science:

  • Oncology
  • Immunology
  • Genomics

Background:

  • Primary liver cancer (PLC) recurrence and treatment resistance are linked to tumor heterogeneity.
  • Accurate patient stratification is crucial for effective treatment selection in PLC.

Purpose of the Study:

  • To develop a novel classification strategy for PLC patients by integrating prognosis risk score, mRNAsi index, and immune characteristics.
  • To associate these subtypes with patient prognosis and drug response.
  • To identify potential therapeutic drugs for specific PLC subtypes.

Main Methods:

  • Integrated analysis of prognosis risk score, mRNAsi index, and immune cell infiltration data.
  • Clustering patients into distinct subtypes based on combined criteria.
  • Correlation analysis between subtypes, patient survival, and drug sensitivity.
Genotyping
Immune microenvironment
Prognostic markers
  • Matching subtype gene expression profiles with drug-induced cell line expression data.

    • Main Results:

    • Four distinct patient subtypes were identified, each associated with different prognoses and drug sensitivities.
    • The mRNAsiH_ICCA subtype exhibited the poorest prognosis.
    • Immune characteristics clustering B (ICC_B) showed broad drug sensitivity.
    • Specific drug responses were observed for low and high mRNAsi groups, including KU-55933, NU7441, and Leflunomide.
    • Potential therapeutic drugs targeting disease signature genes were identified for each subtype.

    Conclusions:

    • A feasible multiple combined typing strategy for PLC was developed.
    • This strategy can guide personalized therapeutic selection for primary liver cancer.
    • The findings support the advancement of precision medicine in oncology.